Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manja Meggendorfer

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Leukemia|August 26, 2023
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targetsMinako Mori, Yasuo Kubota, Arda Durmaz, et al.
Blood|December 8, 2023
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, et al.
Leukemia|August 6, 2020
Complex landscape of alternative splicing in myeloid neoplasmsCourtney E Hershberger, Devlin C Moyer, Vera Adema, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Leukemia|October 20, 2022
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasiaYasuo Kubota, Misam Zawit, Jibran Durrani, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Nature Communications|October 4, 2023
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expressionElizabeth Heyes, Anna S Wilhelmson, Anne Wenzel, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Leukemia|August 26, 2023
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targetsMinako Mori, Yasuo Kubota, Arda Durmaz, et al.
Blood|December 8, 2023
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, et al.
Leukemia|August 6, 2020
Complex landscape of alternative splicing in myeloid neoplasmsCourtney E Hershberger, Devlin C Moyer, Vera Adema, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Leukemia|October 20, 2022
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasiaYasuo Kubota, Misam Zawit, Jibran Durrani, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Nature Communications|October 4, 2023
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expressionElizabeth Heyes, Anna S Wilhelmson, Anne Wenzel, et al.
Pageof 13